Doxycycline calcium 

Doxycycline calcium, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor^[1]. Doxycycline calcium shows antibacterial activity and anti-cancer cell proliferation activity^{[1][2][3][4][5]}.

Doxycycline (0.01-10 µg/mL, 4 d) 仅在高浓度下影响胶质瘤细胞的生长^[2]。
Doxycycline (0.01-10 µg/mL, 24 h) 浓度为 1 µg/mL 及更高时降低 SVG 细胞中 MT-CO1 蛋白含量^[2]。
Doxycycline (100 ng/mL, 1 µg/mL; 24 h) 降低人细胞系的增殖^[4]。
Doxycycline (0-250 μM, 72 h) 抑制乳腺癌细胞的活性^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Doxycycline (口服; 200, 800 mg/kg; 每天一次; 3 月) 以剂量依赖的方式降低未治疗 HT 小鼠的 MMP-9 活性^[3]。
Doxycycline 和 Tetracycline (HY-A0107) 从上消化道吸收后起全身作用。多西环素比四环素的主要优点是其活性更长，并且可以每天服用两次或一次。两种药物的峰浓度相似，但多西环素达到峰浓度的时间更短，半衰期明显更长^[6]。

Doxycycline (Dox) 在分子生物学研究中常被用作诱导剂，用于诱导基因表达。在构建了四环素诱导表达系统（Tet-On/Tet-Off 系统） 的细胞或模型动物中，可以通过添加或去除 Dox 来精确控制目标基因的表达^{[7][8][9][10]}。

Dox 诱导模型剂量参考^{[7][8][9][10]}：
（1）模式动物：雄性 Sprague–Dawley 大鼠
Tet regulatory system：Dox 以 20-3000 ppm 混于饲料中供应
（2）模式动物：Cags小鼠
Tet regulatory system：Dox 以 625 ppm 混于饲料中供应
（3） 模式动物：转基因 Wistar 大鼠
Tet regulatory system：Dox 以 2 mg/mL 溶解于饮用水中供应
（4）模式动物：转基因 NRMI 近交系小鼠
Tet regulatory system：Dox 以 2 mg/mL 溶解于饮用水中供应

Dox 的溶解方法参考^[9][10]：
（1）配置 Dox 工作液
将 100 mg Dox 加入 50 mL 饮用水中溶解，加入 5% 蔗糖或 2% 糖精遮掩苦味，每三天更换一次。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

524.59

C₂₂H₂₄Ca₂N₂O₈

94088-85-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Eusebio Manchado, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016 Jun 30;534(7609):647-51.  [Content Brief]

  [2]. Anna-Luisa Luger, et al. Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems. Int J Mol Sci. 2018 May 17;19(5):1504.  [Content Brief]

  [3]. Wilfried Briest, et al. Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome. J Pharmacol Exp Ther. 2011 Jun;337(3):621-7.  [Content Brief]

  [4]. Ethan Ahler, et al. Doxycycline alters metabolism and proliferation of human cell lines. PLoS One. 2013 May 31;8(5):e64561.  [Content Brief]

  [5]. Le Zhang, et al. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle. 2017 Apr 18;16(8):737-745.  [Content Brief]

  [6]. Niv Y. Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis. Digestion. 2016;93(2):167-73.  [Content Brief]

  [7]. Manfredsson FP, et al. Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol Ther. 2009 Nov;17(11):1857-67.  [Content Brief]

  [8]. Redelsperger IM, et al. Stability of Doxycycline in Feed and Water and Minimal Effective Doses in Tetracycline-Inducible Systems. J Am Assoc Lab Anim Sci. 2016;55(4):467-74.  [Content Brief]

  [9]. Konopka W, et al. Tet system in the brain: transgenic rats and lentiviral vectors approach. Genesis. 2009 Apr;47(4):274-80.  [Content Brief]

  [10]. Kistner A, et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8.  [Content Brief]